Justine
Justine Cheval, Paris FR
Patent application number | Description | Published |
---|---|---|
20130345400 | IDENTIFICATION OF A HUMAN GYROVIRUS AND APPLICATIONS - The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject. | 12-26-2013 |
20140024017 | IDENTIFICATION OF A NOVEL HUMAN POLYOMAVIRUS (IPPyV) AND APPLICATIONS - The invention relates to the identification of a novel human polyomavirus species (designated IPPyV) and applications derived from the identified features and properties of this virus. The IPPy virus species of the invention qualifies as a human virus, in view of the fact that it is capable of infecting a human host. Having identified a novel human polyomavirus species, IPPyV, the inventors have been able to propose means for the detection of exposure or infection by such a virus, especially detection in a biological sample previously obtained from a human host. The invention also concerns means suitable for obtaining an immune response in a host with a view to prevent the onset or the development of an infection with an IPPyV. | 01-23-2014 |
20150132260 | Anellovirus Genome Quantification as a Biomarker of Immune Suppression - The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment. | 05-14-2015 |
Justine Rembisz, Pittsburgh, PA US
Patent application number | Description | Published |
---|---|---|
20130113186 | Lightweight collapsible stroller - A stroller is provided which includes a right frame and a left frame. Each frame has a front support rotatably connected to a rear support at a frame joint. The front support of each frame is a telescoping tube assembly. The stroller further includes a linkage comprising at least two substantially rigid members connected between the right frame and the left frame, the rigid members being connected to the front supports at a right slideable joint and a left slidable joint. The joints are received within the slot of the outer tube. A drive mechanism coupled to the right or left frame is also provided. The front support and the rear support of the right frame and the left frame are movable from an open position to a closed position by the drive mechanism. | 05-09-2013 |
20140035261 | Lightweight Collapsible Stroller - Provided herein is a lightweight stroller that can be transitioned between a closed position and an open position. The stroller includes a seating portion and at least one frame supporting the seating portion and transitionable from an open position to a closed position. The frame includes at least a front support rotatably connected to rear support. The stroller also includes a cinching strap connected between the front support and the rear support. The cinching strap is configured such that, as the frame transitions from the open position to the closed position, the cinching strap pulls the rear support toward the front support or the front support toward the front support. The cinching strap may at least partially maintain the front support and the rear support in the closed position. The cinching strap may include a flexible portion formed from a string, cable, polymer sheet, braided webbing, or any combination thereof. | 02-06-2014 |
20150175188 | LIGHTWEIGHT COLLAPSIBLE STROLLER - A stroller is provided, which includes a frame and a drive mechanism coupled to the frame and configured to transition the frame between an open position and a closed position. The drive mechanism includes: a cable drive; at least one spool rotated by the cable drive; at least one cable received by the at least one spool and connected to the frame; and at least one biasing member connected to the at least one cable for removing slack from the at least one cable. The stroller is configured such that rotation of the at least one spool by the cable drive causes the cable to exert a force against the frame to transition the frame between the open position and the closed position or between the closed position and the open position. | 06-25-2015 |
Justine Tigno-Aranjuez, Shaker Heights, OH US
Patent application number | Description | Published |
---|---|---|
20130005726 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - A method for treating in a subject with an inflammatory disorder and/or immunological disorder associated with NOD2 activation includes administering to the subject a therapeutically effective amount of at least one tyro sine kinase inhibitor that substantially inhibits nucleotide-binding oligomerization domain containing 2 (NOD2):receptor-interacting protein 2 (RIP2) signaling in a NOD2-bearing cell and is not cytotoxic to the cell. | 01-03-2013 |
Justine Tigno-Aranjuez, Cleveland, OH US
Patent application number | Description | Published |
---|---|---|
20150292012 | BIOMARKERS FOR NOD2 AND/OR RIP2 ACTIVITY RELATED APPLICATION - A method of predicting RIP2 inhibitor efficacy in treating a subject with an inflammatory disorder includes obtaining a bodily sample from the subject, determining in the bodily sample the expression level(s) of at least one gene selected from the group consisting of cd40, Clec4E, clec5a, CxCL10, gpr84, Icam1, Irgl, Marcks11, pde4b, Ptges, Rasgrp1, and slc2a6,comparing the expression levels of the at least one gene with the corresponding control value(s), and characterizing the subject as being responsive to RIP2 inhibitor treatment if the expression levels of the at least one gene is increased compared to the corresponding control value(s). | 10-15-2015 |